One ARK Invest exchange-traded fund run by ETF star Cathie Wood bought over 4.1 million shares of Soaring Eagle Acquisition Corp. (NASDAQ: SRNG) on Wednesday, as the share price of this fund traded up less than 1% in the day’s session. The fund’s share price has greatly improved over the past year.

Specifically, ARK Genomic Revolution ETF (NYSEARCA: ARKG) bought 4,144,190 shares of the special purpose acquisition company (SPAC). At Wednesday’s closing price, this would have valued this purchase at roughly $41 million. This is only a small fraction of the total holdings. This fund is up 50% over the past 52 weeks.

Here is a quick look at all the purchases made by ARK ETFs:

Fund	Ticker	Company	Shares
ARKG	BEAM	Beam Therapeutics	17,964
ARKG	SGFY	Signify Health	484,603
ARKG	SMFR	Sema4	179,239
ARKG	NVTA	Invitae	25,000
ARKG	SRNG	Soaring Eagle Acquisition	4,144,190
ARKG	MASS	908 Devices	2,401
ARKG	FATE	Fate Therapeutics	82,289
ARKG	CRSP	CRISPR Therapeutics	12,743
ARKG	ZY	Zymergen	2,469,102
ARKG	RPTX	Repare Therapeutics	7,962
ARKK	VCYT	Veracyte	5,000
ARKK	PATH	UiPath	324,106
ARKK	FATE	FATE Therapeutics	30,751
ARKK	EDIT	Editas Medicine	14,844
ARKQ	MKFG	Markforged	435,263
ARKQ	KTOS	Kratos Defense & Security Solutions	284,321
ARKQ	AVAV	Aerovironment	22,724
ARKW	PD	PagerDuty	30,000
ARKW	LPSN	LivePerson	251,511
ARKW	VUZI	Vuzix	25,000

Catherine Wood, the CEO and CIO of ARK Investment Management, is a minority and nonvoting shareholder of 24/7 Wall St.

Get Our Free Investment Newsletter

I have read, and agree to the Terms of Use

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.